Amgen’s ninth edition of its Biosimilar Trends Report explores the evolution of the US biosimilar industry, including current trends, predictions for the next few years, advice for stakeholders going forward, and insight into how reimbursement and other policies could develop.
Amgen released its ninth edition of its Biosimilar Trends Report, giving an extensive look at the current state of the market for biosimilars, which the company says has driven $21 billion in savings over the past 6 years.
Since 2015, 39 biosimilars have been approved by the FDA and 24 have launched. Overall, the average sales price (ASP) of reference products and biosimilars is dropping. The prices have gone down at a negative compound annual growth rate of -9% to -24% for biosimilars and -4% to -21% for originators. In addition, biosimilars have an average of 75% market share if they launched during 2019 and 39% share during the first 3 years if they launched before 2019.
The report predicted a greater expansion of biosimilars in the pharmacy benefit space, biosimilars in more therapeutic classes, and more approvals and launches for interchangeable biosimilars. Additionally, the report noted some of the biggest regulatory policies that have impacted biosimilars in 2022, including the passage of the Advancing Education on Biosimilars Act, the reauthorization of the Biosimilar User Fee Act for 2023-2027, and the Inflation Reduction Act.
“We anticipate biosimilars in 2022 to continue the promise of cost savings to have the potential to increase access to patients. This year will prove pivotal for the pharmacy benefit space, as providers and pharmacists navigate the first interchangeable biosimilar insulin listed as preferred on several national formularies,” said Beth McMahon, senior vice president of emerging therapies and channel strategy at AmerisourceBergen, in the report.
In addition to more legislation and more biosimilars, the number of development programs that are participating in the FDA’s Biosimilar Development Program has risen from 77 programs in March 2019 to 96 programs in March 2022, despite a slow increase in 2020 as a result of the COVID-19 pandemic.
Biosimilars in the medical benefit typically launched at a wholesale acquisition cost (WAC) that is between 10% and 57% lower than the WAC of the originator.
The report noted the successful uptake of oncology biosimilars, which account for nearly 80% market share in the trastuzumab and bevacizumab markets and 64% of the rituximab market share. Despite biologics representing half of the therapies used in treating cancer, the high cost associated with them results in much greater costs in development and production compared to small molecule drugs.
“The price takes its own toll on cancer patients with [more] patients facing out-of-pocket costs. It becomes hard for them to sustain the level of cancer care. I think biosimilars definitely help assimilate some of that kind of challenge,” said Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care.
Trastuzumab biosimilars have led to a 19% price drop in the reference product (Herceptin) and bevacizumab biosimilars have resulted in a 15% decline in Avastin’s (reference bevacizumab) price. Rituximab biosimilars have led to an 11% drop in the ASP of Rituxan (reference rituximab) and are priced between 51% and 56% lower than the reference product.
Additionally, biosimilars account for 42% of the pegfilgrastim market and generated $724 million in savings by the second quarter of 2022 (Q2 2022). Filgrastim biosimilars are also priced between 60% and 81% lower than the reference product (Neupogen) and account for 82% of all filgrastim products.
The presence of 1 epoetin alfa biosimilar has resulted in significant price declines for the biosimilar and the reference product (Epogen/Procrit), both experiencing over a 30% decrease from the ASP of the reference product in the fourth quarter of 2018, when the biosimilar launched.
Infliximab biosimilars have experienced a tougher adoption journey. Although the ASP of the originator Remicade has dropped 57% since the onset of biosimilar competition, infliximab biosimilars still trail behind the reference product in market share (42% vs 54%, respectively). However, infliximab biosimilars have still resulted in $660 million in savings in Q2 2022.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.